1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01

M. Brandão, J.T.J.N. Hiltermann, E. Wauters, B.J. Solomon,E. Castanon Alvarez, E. Felip, E.H. Gort, H. Izumi,D-W. Kim, L. Paz-Ares, K.S. Rohrberg, L. Steinbusch, T. Yoshida, H. Chen, S. Colebrook, I. Achour, M. Origuchi, F. Aroldi,B.C. Cho

Annals of Oncology（2023）

引用 0|浏览6

暂无评分

关键词

checkpoint inhibitor,bispecific antibody,non-small-cell non-small-cell lung cancer,lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要